Search

Author/Creator Christopoulou, A

2. P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC). (1st November 2019)

Authors:
Christopoulou, A; Marmé, F; Oaknin, A; Lorusso, D; Safra, T; Lindahl, G; Chudecka-Glaz, A; Ciuleanu, T; Collins, DC; Demirkiran, F; Lifrenko, I; Van Gorp, T; Coleman, RL; Fujiwara, K; Oza, AM; Westin, SN; O'Malley, DM; Herzog, TJ; Eskander, R; Wilson, M
Journal:
International journal of gynecological cancer
Issue:
Volume 29(2019)Supplement 4
Page Start:
A130
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. (22nd June 2019)

Authors:
Souglakos, J; Boukovinas, I; Kakolyris, S; Xynogalos, S; Ziras, N; Athanasiadis, A; Androulakis, N; Christopoulou, A; Vaslamatzis, M; Ardavanis, A; Emmanouilides, C; Bompolaki, I; Kourousis, C; Makrantonakis, P; Christofyllakis, C; Athanasiadis, E; Kentepozidis, N; Karampeazis, A; Katopodi, U; An...
Journal:
Annals of oncology
Issue:
Volume 30:Number 8(2019)
Page Start:
1304
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗